CSF1R and cancer: The most-cited paper among the 134 articles was Pexidartinib, a Novel Small-Molecule CSF-1R Inhibitor for TGCT: Systematic Review of Preclinical and Clinical Development (Table 1) (2, 13–21), published by Brooke Benner at the Ohio State University Comprehensive Cancer Center in 2020.